Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.70 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecyl Gallate SCHEMBL20450222 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Octadecyl Gallate SCHEMBL29648937 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Octyl_Gallate SCHEMBL29883664 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Hexadecyl Gallate SCHEMBL29376835 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Gallic Acid SCHEMBL6897461 | 0.86 | KAT8 (0.49) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Gallic Acid SCHEMBL29061494 | 0.86 | KAT8 (0.49) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28459672 | 0.86 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28591660 | 0.86 | ESR1 (0.61) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2292179 | 0.86 | ESR1 (0.63) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Propyl Gallate SCHEMBL29361471 | 0.85 | SERPINE1 (0.56) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4555329-A1 | SAMPLE COLLECTION APPARATUS | NIGHTINGALE HEALTH OYJ (FI) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015491-A1 | SAMPLE COLLECTION APPARATUS | RENEGADEXBIO, PBC (US) | 2024-01-18 | — | — | WO | claimed |
| CN-122028922-A | Method for treating diabetic macular edema | 奥库里斯经营管理有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20250387411-A1 | PH STABILIZED OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250275997-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | BONAFIDE HEALTH, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12403148-B2 | PH stabilized ophthalmic compositions | Oculis Operations Sàrl (CH) | 2025-09-02 | — | — | US | disclosed |
| US-12403147-B2 | Treatment of ocular inflammation following ocular surgery | Oculis Operations Sàrl (CH) | 2025-09-02 | — | — | US | disclosed |
| US-12397000-B2 | Stabilized ophthalmic dexamethasone compositions | Oculis Operations Sàrl (CH) | 2025-08-26 | — | — | US | disclosed |
| US-12397002-B2 | PH stabilized ophthalmic dexamethasone compositions | Oculis Operations Sàrl (CH) | 2025-08-26 | — | — | US | disclosed |
| US-20220354869-A1 | METHOD FOR STABILIZING THE PH OF AN AQUEOUS COMPOSITION COMPRISING A DRUG | Oculis Operations Sàrl (CH) | 2022-11-10 | — | — | US | disclosed |
| US-20220193107-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | BONAFIDE HEALTH, LLC | 2022-06-23 | — | — | US | disclosed |
| EP-3313400-B1 | ISOXAZOLINE SOLUTION CONTAINING VITAMIN E FOR USE WITH SANITIZED DRINKING WATER | INTERVET INT BV (NL) | 2022-06-15 | — | — | EP | disclosed |
| EP-3315145-B1 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED COLLAGEN LAYER | BSN MEDICAL GMBH (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-3993807-A1 | METHOD FOR STABILIZING THE PH OF AN AQUEOUS COMPOSITION COMPRISING A DRUG | Oculis SA (CH) | 2022-05-11 | — | — | EP | disclosed |
| US-20220119569-A1 | Curable and Solvent Soluble Formulations and Methods of Making and Using Therof | POLY6 TECHNOLOGIES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220031729-A1 | USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION | Zentar LLC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20110192416-A1 | USE OF HYDROPHOBIN FOR NON-PERMANENT DYEING OF KERATIN | BASF SE (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193107-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20250387411-A1 | PH STABILIZED OPHTHALMIC COMPOSITIONS | PDE6D, EYA3, EYA2 | ESR1 3084/4885AKR1C4 3633/4885AKR1C3 3543/4885 |
| US-20250275997-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20220040145-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | APP, PSEN1, BACE1 | ESR1 4786/4885AKR1C4 3440/4885AKR1C3 2809/4885 |
| US-20220031729-A1 | USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION | BHMT2, BHMT, MAT2A | ESR1 1471/4885AKR1C4 2867/4885AKR1C3 2623/4885 |
| US-20110192416-A1 | USE OF HYDROPHOBIN FOR NON-PERMANENT DYEING OF KERATIN | KRT18, VIM, CD68 | ESR1 4358/4885AKR1C4 838/4885AKR1C3 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.